Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 97Lung Neoplasms 35Colorectal Neoplasms 35Pancreatic Neoplasms 13Adenocarcinoma of Lung 10Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Neoplasm Metastasis 8Head and Neck Neoplasms 8Colonic Neoplasms 7Carcinoma, Renal Cell 7Ovarian Neoplasms 6Breast Neoplasms 6Rectal Neoplasms 5Melanoma 5Endometrial Neoplasms 5Stomach Neoplasms 4Adenocarcinoma, Bronchiolo-Alveolar 4Triple Negative Breast Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Recurrence 2Pleural Effusion, Malignant 2Esthesioneuroblastoma, Olfactory 2Carcinoma, Pancreatic Ductal 2

Interventions

Carboplatin 12Pemetrexed 11pembrolizumab 10Paclitaxel 6Cisplatin 6Erlotinib Hydrochloride 5Docetaxel 5Nivolumab 4Gefitinib 4spartalizumab 3osimertinib 3Gemcitabine 3EC145 3Crizotinib 3Afatinib 3technetium 99m etarfolatide 2pralsetinib 2fludarabine 2cemiplimab 2brigatinib 2alpha-2'-deoxythioguanosine 2aldesleukin 2Vinorelbine 2Radiotherapy 2Quality of Life 2MORAb-202 2Immunotherapy 2Drug Therapy 2Cyclophosphamide 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × Cetuximab × Thoracic × Clear all
NCT00716456 2015-04-30

Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
21 enrolled 8 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡